104162-47-2Relevant articles and documents
Mono- and dicationic short PEG and methylene dioxyalkylglycerols for use in synthetic gene delivery systems
Hurley, Christopher A.,Wong, John B.,Ho, Jimmy,Writer, Michele,Irvine, Scott A.,Lawrence, M. Jayne,Hart, Stephen L.,Tabor, Alethea B.,Hailes, Helen C.
, p. 2554 - 2559 (2008)
A range of monocationic and dicationic dioxyalkylglycerol cytofectins have been synthesised possessing methylene and short n-ethylene glycol spacers. The monocationic compounds were found to be effective in transfections when formulated as lipopolyplexes with peptide and DNA components, in particular with shorter PEG head groups which may have less effect on peptide targeting in the ternary complex. The Royal Society of Chemistry 2008.
A highly efficient approach for the synthesis of cationic lipid DOSPA
Li, Yanhong,Debs, Robert J.,Heath, Timothy D.
, p. 2284 - 2286 (2006)
A highly efficient strategy has been developed for the synthesis of the cationic lipid, N-[2-({2,5-bis[(3-aminopropyl)amino]-1-oxopentyl}amino)ethyl]-N, N-dimethyl-2,3-bis[(1-oxo-9-octadecenyl)oxy] salt with hydrogen chloride (DOSPA). It involves the linkage of a cationic head group and a hydrophobic moiety in the presence of the standard coupling reagents. Georg Thieme Verlag Stuttgart.
A scalable, extrusion-free method for efficient liposomal encapsulation of plasmid DNA
Jeffs, Lloyd B.,Palmer, Lorne R.,Ambegia, Ellen G.,Giesbrecht, Cory,Ewanick, Shannon,MacLachlan, Ian
, p. 362 - 372 (2005)
Purpose. A fully scalable and extrusion-free method was developed to prepare rapidly and reproducibly stabilized plasmid lipid particles (SPLP) for nonviral, systemic gene therapy. Methods. Liposomes encapsulating plasmid DNA were formed instantaneously by mixing lipids dissolved in ethanol with an aqueous solution of DNA in a controlled, stepwise manner. Combining DNA-buffer and lipid-ethanol flow streams in a T-shaped mixing chamber resulted in instantaneous dilution of ethanol below the concentration required to support lipid solubility. The resulting DNA-containing liposomes were further stabilized by a second stepwise dilution. Results. Using this method, monodisperse vesicles were prepared with particle sizes less than 200 nm and DNA encapsulation efficiencies greater than 80%. In mice possessing Neuro 2a tumors, SPLP demonstrated a 13 h circulation half-life in vivo, good tumor accumulation and gene expression profiles similar to SPLP previously prepared by detergent dialysis. Cryo transmission electron microscopy analysis showed that SPLP prepared by stepwise ethanol dilution were a mixed population of unilamellar, bilamellar, and oligolamellar vesicles. Vesicles of similar lipid composition, prepared without DNA, were also A similar approach was used to prepare neutral egg phosphatidylcholine:cholesterol (EPC:Chol) liposomes possessing a pH gradient, which was confirmed by the uptake of the lipophilic cation safranin O. Conclusions. This new method will enable the scale-up and manufacture of SPLP required for preclinical and clinical studies. Additionally, this method now allows for the acceleration of SPLP formulation development, enabling the rapid development and evaluation of novel carrier systems.
LIPID ENCAPSULATING INTERFERING RNA
-
Paragraph 0248, (2016/05/24)
Rich tooling is provided for REST application development that integrates the exploration of a REST API, modeling of data types and the REST API, and the generation of artifacts using the modeled REST API and data types.
IMPROVED COMPOSITIONS AND METHODS FOR THE DELIVERY OF NUCLEIC ACIDS
-
Paragraph 0216;0224, (2016/08/17)
The present invention provides compositions and methods for the delivery of therapeutic agents to cells. In particular, these include novel lipids and nucleic acid-lipid particles that provide efficient encapsulation of nucleic acids and efficient delivery of the encapsulated nucleic acid to cells in vivo. The compositions of the present invention are highly potent, thereby allowing effective knock-down of specific target protein at relatively low doses. In addition, the compositions and methods of the present invention are less toxic and provide a greater therapeutic index compared to compositions and methods previously known in the art.
Method for the non-radioactive measurement of the nucleic acid synthesis in eukaryotic cells
-
, (2008/06/13)
For the determination of the rate of nucleic acid synthesis in eukaryotic cells a nucleotide which is non-radioactively labelled or derivatized with a hapten is introduced into the cells with the addition of liposomes and the rate of synthesis of the nucleic acids is determined by means of the incorporation of the nucleotide via its label or derivatization.
Cationic lipids
-
, (2008/06/13)
The present invention discloses cationic lipids useful for making lipid aggregates for delivery of macromolecules and other compounds into cells. They are especially useful for the DNA-dependent transformation of cells. Also disclosed are lipids useful both for the delivery of macromolecules and also useful as intermediates for making other such lipids.
N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
-
, (2008/06/13)
This invention relates to compounds of the formula STR1 or an optical isomer thereof wherein R1 and R2 are the same or different and are an alkyl or alkenyl group of 6 to 24 carbon atoms; R3, R4 and R5 are the same or different and are alkyl of 1 to 8 carbon atoms, aryl, aralkyl of 7 to 11 carbon atoms, or when two or three of R3, R4, and R5 are taken together to form quinuclidino, piperidino, pyrrolidino, or morpholino; n is 1 to 8; and X is a pharmaceutically acceptable anion.
